CRISPR-Cas Clinical Trial Update
Nov. 17, 2020
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Shanghai BDgene Technology
Main focus: mRNA-mediated delivery of gene-editing systems
Company stage: Clinical
Diseases: wet age-related macular degeneration (wAMD), glucoma, multiple other undisclosed diseases
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai, China
Website: https://bdgenetherapeutics.com/
Shanghai BDgene Technology uses it proprietary technology, BDmRNA, to deliver gene-editing systems for the treatment of genetic diseases. The technology is thought to reduce the probability of off-target gene editing, and improve the safety of gene-editing medicines. Currently, the company is developing multiple pre-clinical programmes.
Tags
Shanghai BDgene Technology Co., Ltd.
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
